Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

HL-032: Nivolumab and Brentuximab Vedotin (BV)–Based, Response-Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study

Peter D. Cole,Christine Mauz-Körholz,Maurizio Mascarin,Gérard Michel,Stacy Cooper,Auke Beishuizen,Kasey J. Leger,Loredana Amoroso,Salvatore Buffardi,Charlotte Rigaud,Markus Puhlmann,Stephen Francis,Mariana Sacchi,Richard A. Drachtman,Paul Harker-Murray,Thierry Leblanc,Stephen Daw,Kara M. Kelly

Clinical Lymphoma Myeloma and Leukemia（2020）

Cited 0|Views4
No score
Key words
Hodgkin lymphoma,children,adolescents,young adults,relapsed/refractory,nivolumab,brentuximab vedotin,HL
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined